{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:16:04Z","timestamp":1790615764668,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jpsychires.2026.07.005","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T06:38:14Z","timestamp":1783665494000},"page":"549-562","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical effectiveness of pharmacogenomic-guided antidepressant treatment in adult major depressive disorder: systematic review and exploratory platform-aware meta-analysis"],"prefix":"10.1016","volume":"201","author":[{"given":"Ilaria","family":"Pullano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Iazzolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Di Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Monaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Miola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Fornaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7077-3506","authenticated-orcid":false,"suffix":"jr.","given":"Luca","family":"Steardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jpsychires.2026.07.005_bib1","first-page":"145","article-title":"Clinical utility of combinatorial pharmacogenomics-guided antidepressant therapy: evidence from three clinical studies","volume":"1","author":"Altar","year":"2015","journal-title":"Mol. Neuropsychiatry"},{"issue":"7","key":"10.1016\/j.jpsychires.2026.07.005_bib2","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1176\/appi.ajp.20230657","article-title":"Pharmacogenomic clinical support tools for the treatment of depression","volume":"181","author":"Baum","year":"2024","journal-title":"Am. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.jpsychires.2026.07.005_bib3","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.3390\/ph18091360","article-title":"Pharmacogenetics and the response to antidepressants in major depressive disorder","volume":"18","author":"Bertollo","year":"2025","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.jpsychires.2026.07.005_bib4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2217\/pgs-2018-0142","article-title":"Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials","volume":"20","author":"Bousman","year":"2019","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1016\/j.jpsychires.2026.07.005_bib5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/a-1288-1061","article-title":"Review and consensus on pharmacogenomic testing in psychiatry","volume":"54","author":"Bousman","year":"2021","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"10.1016\/j.jpsychires.2026.07.005_bib8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/cpt.2903","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants","volume":"114","author":"Bousman","year":"2023","journal-title":"Clin. Pharmacol. Therapeut."},{"issue":"5","key":"10.1016\/j.jpsychires.2026.07.005_bib6","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41397-018-0027-3","article-title":"Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools","volume":"18","author":"Bousman","year":"2018","journal-title":"Pharmacogenomics J."},{"issue":"6","key":"10.1016\/j.jpsychires.2026.07.005_bib7","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S2215-0366(16)00017-1","article-title":"Commercial pharmacogenetic-based decision-support tools in psychiatry","volume":"3","author":"Bousman","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.07.005_bib9","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jpsychires.2017.09.024","article-title":"Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: a randomized clinical trial demonstrating clinical utility","volume":"96","author":"Bradley","year":"2018","journal-title":"J. Psychiatr. Res."},{"issue":"10","key":"10.1016\/j.jpsychires.2026.07.005_bib10","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41431-021-01004-7","article-title":"Dutch pharmacogenetics working group (DPWG) guideline for the gene\u2013drug interaction between CYP2C19 and CYP2D6 and SSRIs","volume":"30","author":"Brouwer","year":"2022","journal-title":"Eur. J. Hum. Genet."},{"issue":"8","key":"10.1016\/j.jpsychires.2026.07.005_bib12","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2217\/pgs-2019-0157","article-title":"The clinical utility of combinatorial pharmacogenomic testing for patients with depression: a meta-analysis","volume":"21","author":"Brown","year":"2020","journal-title":"Pharmacogenomics"},{"issue":"6","key":"10.1016\/j.jpsychires.2026.07.005_bib11","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/cpt.2748","article-title":"Pharmacogenomic testing and depressive symptom remission: a systematic review and meta-analysis of prospective, controlled clinical trials","volume":"112","author":"Brown","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jpsychires.2026.07.005_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115102","article-title":"Evaluating treatment outcomes in pharmacogenomic-guided care for major depression: a rapid review and meta-analysis","volume":"321","author":"Bunka","year":"2023","journal-title":"Psychiatry Res."},{"issue":"6","key":"10.1016\/j.jpsychires.2026.07.005_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/gpsych-2023-101050","article-title":"Effectiveness of pharmacogenomics on the response and remission of treatment-resistant depression: a meta-analysis of randomised controlled trials","volume":"36","author":"Cheng","year":"2023","journal-title":"Gen. Psychiatry"},{"issue":"3","key":"10.1016\/j.jpsychires.2026.07.005_bib15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.jpsychires.2026.07.005_bib16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.euroneuro.2025.08.003","article-title":"Efficacy of pharmacogenetic (PGx)-guided antidepressant treatment on functional outcomes and quality of life in adults with anxiety and affective disorders: a systematic review and meta-analysis","volume":"100","author":"Fares-Otero","year":"2025","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jpsychires.2026.07.005_bib17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jpsychires.2019.01.003","article-title":"Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: a large, patient- and rater-blinded, randomized, controlled study","volume":"111","author":"Greden","year":"2019","journal-title":"J. Psychiatr. Res."},{"issue":"7650","key":"10.1016\/j.jpsychires.2026.07.005_bib18","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.jpsychires.2026.07.005_bib19","doi-asserted-by":"crossref","first-page":"469","DOI":"10.9758\/cpn.2018.16.4.469","article-title":"A pharmacogenomic-based antidepressant treatment for patients with major depressive disorder: results from an 8-week, randomized, single-blinded clinical trial","volume":"16","author":"Han","year":"2018","journal-title":"Clin. Psychopharmacol. Neurosci."},{"issue":"4","key":"10.1016\/j.jpsychires.2026.07.005_bib20","doi-asserted-by":"crossref","first-page":"641","DOI":"10.9758\/cpn.2020.18.4.641","article-title":"Corrigendum: a pharmacogenomic-based antidepressant treatment for patients with major depressive disorder: results from an 8-week, randomized, single-blinded clinical trial","volume":"18","author":"Han","year":"2020","journal-title":"Clin. Psychopharmacol. Neurosci."},{"issue":"11","key":"10.1016\/j.jpsychires.2026.07.005_bib21","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med."},{"issue":"5","key":"10.1016\/j.jpsychires.2026.07.005_bib22","first-page":"25nr03970","article-title":"Toward precision psychiatry: innovations and prospects in treating depression","volume":"27","author":"Laifenfeld","year":"2025","journal-title":"Prim. Care Companion CNS Disord."},{"issue":"4","key":"10.1016\/j.jpsychires.2026.07.005_bib23","doi-asserted-by":"crossref","first-page":"435","DOI":"10.31887\/DCNS.2009.11.4\/afleuchter","article-title":"A new paradigm for the prediction of antidepressant treatment response","volume":"11","author":"Leuchter","year":"2009","journal-title":"Dialogues Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.jpsychires.2026.07.005_bib24","article-title":"Effectiveness of pharmacogenomic testing across age groups for depressive disorder treatment and its age-dependent effects on cognitive function: a randomized controlled trial","volume":"398","author":"Li","year":"2026","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jpsychires.2026.07.005_bib26","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.euroneuro.2024.01.005","article-title":"Current level of evidence for improvement of antidepressant efficacy and tolerability by pharmacogenomic-guided treatment: a systematic review and meta-analysis of randomized controlled clinical trials","volume":"81","author":"Milosavljevi\u0107","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.jpsychires.2026.07.005_bib27","doi-asserted-by":"crossref","DOI":"10.1192\/j.eurpsy.2025.10132","article-title":"Does pharmacogenetic testing optimize antidepressant effectiveness in major depressive disorder? Data from a double-blind randomized controlled trial in a real-world clinical setting","volume":"68","author":"Minelli","year":"2025","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.07.005_bib28","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1186\/s13063-021-05775-8","article-title":"Clinical validation of a combinatorial PharmAcogeNomic approach in major depressive disorder: an observational prospective RAndomized, participant and rater-blinded, controlled trial (PANDORA trial)","volume":"22","author":"Minelli","year":"2021","journal-title":"Trials"},{"issue":"2","key":"10.1016\/j.jpsychires.2026.07.005_bib29","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2022.9805","article-title":"Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder: the PRIME care randomized clinical trial","volume":"328","author":"Oslin","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jpsychires.2026.07.005_bib30","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.jpsychires.2026.07.005_bib31","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3390\/jpm15120616","article-title":"Personalizing antidepressant therapy: integrating pharmacogenomics, therapeutic drug monitoring, and digital tools for improved depression outcomes","volume":"15","author":"Parshenkov","year":"2025","journal-title":"J. Personalized Med."},{"issue":"9","key":"10.1016\/j.jpsychires.2026.07.005_bib33","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/da.23029","article-title":"Randomized, controlled, participant- and rater-blind trial of pharmacogenomic test-guided treatment versus treatment as usual for major depressive disorder","volume":"37","author":"Perlis","year":"2020","journal-title":"Depress. Anxiety"},{"issue":"10","key":"10.1016\/j.jpsychires.2026.07.005_bib34","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/da.22742","article-title":"Pharmacogenetic testing among patients with mood and anxiety disorders is associated with decreased utilization and cost: a propensity-score matched study","volume":"35","author":"Perlis","year":"2018","journal-title":"Depress. Anxiety"},{"issue":"6","key":"10.1016\/j.jpsychires.2026.07.005_bib35","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/s41576-022-00572-8","article-title":"Pharmacogenomics: current status and future perspectives","volume":"24","author":"Pirmohamed","year":"2023","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.jpsychires.2026.07.005_bib32","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s12888-017-1412-1","article-title":"Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial","volume":"17","author":"P\u00e9rez","year":"2017","journal-title":"BMC Psychiatry"},{"issue":"5\u20136","key":"10.1016\/j.jpsychires.2026.07.005_bib36","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/14622416.2024.2346072","article-title":"Genetic diversity of cytochrome P450 in patients receiving psychiatric care in Greece: a step towards clinical implementation","volume":"25","author":"Ragia","year":"2024","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jpsychires.2026.07.005_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1267294","article-title":"Utility of pharmacogenetic testing to optimise antidepressant pharmacotherapy in youth: a narrative literature review","volume":"14","author":"Roberts","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jpsychires.2026.07.005_bib38","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jad.2018.08.056","article-title":"The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: a meta-analysis","volume":"241","author":"Rosenblat","year":"2018","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jpsychires.2026.07.005_bib39","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jclinepi.2019.12.020","article-title":"GRADE guidelines: 21 part 1. Study design, risk of bias, and indirectness in rating the certainty across a body of evidence for test accuracy","volume":"122","author":"Sch\u00fcnemann","year":"2020","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.jpsychires.2026.07.005_bib40","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.euroneuro.2025.06.011","article-title":"Clinical predictors of treatment resistant depression","volume":"98","author":"Serretti","year":"2025","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jpsychires.2026.07.005_bib41","doi-asserted-by":"crossref","first-page":"960","DOI":"10.3389\/fnins.2019.00960","article-title":"Preliminary clinical investigation of combinatorial pharmacogenomic testing for the optimized treatment of depression: a randomized single-blind study","volume":"13","author":"Shan","year":"2019","journal-title":"Front. Neurosci."},{"issue":"2","key":"10.1016\/j.jpsychires.2026.07.005_bib42","doi-asserted-by":"crossref","first-page":"150","DOI":"10.9758\/cpn.2015.13.2.150","article-title":"Improved antidepressant remission in major depression via a pharmacokinetic pathway polygene pharmacogenetic report","volume":"13","author":"Singh","year":"2015","journal-title":"Clin. Psychopharmacol. Neurosci."},{"issue":"2","key":"10.1016\/j.jpsychires.2026.07.005_bib43","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1590\/1516-4446-2020-0935","article-title":"How can we improve antidepressant adherence in the management of depression? A targeted review and 10 clinical recommendations","volume":"43","author":"Solmi","year":"2021","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.07.005_bib44","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jpsychires.2026.07.005_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1276410","article-title":"Efficacy and safety of pharmacogenomic-guided antidepressant prescribing in patients with depression: an umbrella review and updated meta-analysis","volume":"15","author":"Tesfamicael","year":"2024","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.jpsychires.2026.07.005_bib46","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41398-022-01847-8","article-title":"Clinical utility of combinatorial pharmacogenomic testing in depression: a Canadian patient- and rater-blinded, randomized, controlled trial","volume":"12","author":"Tiwari","year":"2022","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/j.jpsychires.2026.07.005_bib48","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1186\/s12888-023-04756-2","article-title":"Effect of pharmacogenomics testing guiding on clinical outcomes in major depressive disorder: a systematic review and meta-analysis of RCT","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Psychiatry"},{"issue":"89","key":"10.1016\/j.jpsychires.2026.07.005_bib49","first-page":"219","article-title":"A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder","volume":"16","author":"Winner","year":"2013","journal-title":"Discov. Med."},{"issue":"9","key":"10.1016\/j.jpsychires.2026.07.005_bib50","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1176\/appi.ajp.2018.17111282","article-title":"Clinical implementation of pharmacogenetic decision support tools for antidepressant drug prescribing","volume":"175","author":"Zeier","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.07.005_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1544795","article-title":"Trends in research on novel antidepressant treatments","volume":"16","author":"Zelek-Molik","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.jpsychires.2026.07.005_bib52","doi-asserted-by":"crossref","DOI":"10.1136\/bmjment-2025-301726","article-title":"Comparative effectiveness of pharmacogenomic-guided versus unguided antidepressant treatment in major depressive disorder: new insights from subgroup and cumulative meta-analyses","volume":"28","author":"Zhang","year":"2025","journal-title":"BMJ Mental Health"}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395626003699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395626003699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:28:15Z","timestamp":1790612895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395626003699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":50,"alternative-id":["S0022395626003699"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2026.07.005","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical effectiveness of pharmacogenomic-guided antidepressant treatment in adult major depressive disorder: systematic review and exploratory platform-aware meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2026.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}